HMGB1 and ovarian cancer: Considering that HMGB1 and HMGB2 proteins have been associated to drug resistance during cancer treatment [13,16] we also reviewed available literature to see whether the proteins detected in our interactome study could also be related to this unfavorable event in ovary cancer treatment.